InterShunt
Private Company
Funding information not available
Overview
InterShunt is a private, pre-revenue medical device company founded in 2020, targeting the large and growing heart failure market. Its core innovation is a mechanical, transcatheter system that excises tissue to form a left-to-right atrial shunt, offering a potential new treatment for patients with limited options. The company is led by a team with clinical and device development experience and is currently in the pre-clinical or early clinical development stage. Success hinges on demonstrating the safety and durable efficacy of its novel, implant-free approach in a competitive landscape.
Technology Platform
A proprietary, mechanical transcatheter system that excises tissue from the interatrial septum to create a calibrated, left-to-right shunt for relieving elevated left atrial pressure in heart failure. The system requires no permanent implant or energy source.
Opportunities
Risk Factors
Competitive Landscape
The interatrial shunt space includes established competitors like Edwards Lifesciences (AFX System) and V-Wave, which utilize permanent implants and have advanced clinical programs. InterShunt's key differentiation is its mechanical, no-implant approach, but it must demonstrate comparable or superior clinical outcomes to succeed in this emerging but competitive field.